InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD 41.58
-4.74 (-10.23%)
At close: May 29, 2026
HKG:3696 Revenue
In the year 2025, InSilico Medicine Cayman TopCo had annual revenue of $56.24M USD, down -34.48%. InSilico Medicine Cayman TopCo had revenue of $28.78M in the half year ending December 31, 2025.
Revenue
$56.24M
Revenue Growth
-34.48%
P/S Ratio
54.37
Revenue / Employee
$177.41K
Employees
317
Market Cap
23.80B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.24M | -29.60M | -34.48% |
| Dec 31, 2024 | 85.83M | 34.65M | 67.71% |
| Dec 31, 2023 | 51.18M | 21.03M | 69.77% |
| Dec 31, 2022 | 30.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionInSilico Medicine Cayman TopCo News
- 2 months ago - InSilico Medicine Cayman TopCo Earnings release: Q4 2025 - Filings